FDAnews
www.fdanews.com/articles/73139-curis-doses-first-patient-in-phase-i-trial-for-basal-cell-carcinoma

Curis Doses First Patient in Phase I Trial for Basal Cell Carcinoma

June 8, 2005

Curis has announced that the first patient in the basal cell carcinoma (BCC) Phase I trial has been dosed.

This Phase I clinical trial is being conducted by Genentech and Curis. This drug candidate, a topical antagonist of the Hedgehog signaling pathway, was discovered by Curis and is being co-developed through a collaboration between Genentech and Curis.

The Phase I study is a double-blind, randomized, placebo-controlled study that will enroll approximately 66 subjects with a single or multiple basal cell carcinoma. The study will be conducted at approximately 10 investigational sites in the U.S. The primary outcomes measured in this trial will be the safety and tolerability of a multidose regimen of the Hedgehog antagonist.